By 1987 over a quarter of US symphony players had used heart pills against stage fright
Beta blockers were built to protect hearts, blunting the effect of adrenaline on the body. Musicians soon found they also steadied trembling hands, and a 1987 survey of the 51 largest American orchestras found 27% of players had tried them, mostly supplied by friends rather than doctors. The evidence behind that habit is surprisingly thin.
The drugs work by occupying the receptors that adrenaline and noradrenaline normally switch on, damping the fight-or-flight response. There are three receptor types: beta-1 mainly in the heart and kidneys, beta-2 in the lungs, gut, blood vessels and muscles, and beta-3 in fat cells. Some drugs block all of them, others target one. James Black synthesised the first clinically important ones, propranolol and pronethalol, in 1964, transforming the treatment of angina and earning a place among the major pharmacological advances of the century.
Their main jobs are controlling irregular heart rhythms and lowering the risk of another heart attack. They were once forbidden in heart failure because they weaken the heart's squeeze, until late-1990s trials showed carefully chosen, slowly increased doses cut deaths and hospital stays in stable patients. For high blood pressure they beat a placebo but lag behind diuretics, ACE inhibitors and calcium channel blockers, so they are no longer a usual first choice. A 2025 umbrella review of heart attack survivors found they reduced repeat attacks but not overall deaths in randomised trials, and that the benefit faded over time.
The stage-fright use was first noted in The Lancet in 1976. By blunting a pounding heart, clammy hands and shaking, the drugs let anxious performers concentrate, and similar results from propranolol, which enters the brain, and atenolol, which largely does not, suggest the calming effect is mostly physical. Critics such as the music coach Barry Green argue the performances can sound soulless. Formal evidence for anxiety disorders is weak: a 2025 meta-analysis found no clear benefit over placebo for social phobia or panic disorder, though the studies were few and limited, and the FDA has never approved the drugs for anxiety.
The list of other uses is long, including migraine, glaucoma, an overactive thyroid and the restlessness called akathisia that antipsychotic drugs can cause. Around surgery the picture is mixed, with low-certainty signs of fewer rhythm problems after heart operations but more low blood pressure after others.
Source: Beta blocker
